Editorial : novel and emerging drugs for leukemias.
For the last twenty years, significant progress in molecular and cellular biology has resulted in a better characterization and understanding of the molecular abnormalities in leukemias. These achievements have provided new opportunities for the development of innovative, more effective drugs. Novel therapies are being evaluated both in preclinical studies and in early clinical trials. In this editorial, we demonstrate a brief review of the present insights into new therapeutic strategies for acute and chronic leukemias.